Risperidone

Clozapine Augmentation for Treatment-Resistant Schizophrenia: What Does the Evidence Say?

Up to 30% of patients with treatment-resistant schizophrenia treated with clozapine have residual positive symptoms. Clozapine augmentation is a common approach, but the evidence supporting this practice is limited.
According to the latest evidence, risperidone, lamotrigine, topiramate, or ECT are potential augmenting options.

Read More

Choosing Among Long-Acting Injectable Antipsychotics: Practical Aspects

David N. Osser, MD Associate Professor of Psychiatry Harvard Medical School Brockton Division of the VA Boston Healthcare System   First-generation LAIs (haloperidol, fluphenazine) have higher rates of acute extrapyramidal symptoms, tardive dyskinesia and hyperprolactinemia symptoms compared to most second-generation antipsychotics. However, they have lower costs. Most second-generation antipsychotics cost more than $1000 a month,…

Read More

Antipsychotics for Agitation: Differences Between Tablets, Orally Disintegrating Tablets and Sublingual Formulations

Michael D. Jibson, MD, PhD Professor of Psychiatry Director of Residency Education University of Michigan This presentation discusses how to prescribe oral antipsychotics for acute agitation (standard tablets, orally disintegrating tablets, and a sublingual formulation). Orally disintegrating antipsychotics (Abilify Discmelt, Zyprexa Zydis, Risperdal M-Tab) are not absorbed transmucosally, they have to be swallowed. Orally disintegrating…

Read More

Long-Acting Injectable Antipsychotics: A Practical Guide for Prescribers

Author: Flavio Guzman, MD Competing interests: none This article summarizes the most clinically relevant features of long-acting injectable antipsychotics (LAIs, previously known as depot antipsychotics). We discuss general concepts as well as key prescribing facts of individual agents. The guide also includes two new formulations: aripiprazole lauroxil (Aristada) and 3-month paliperidone palmitate (Invega Trinza). Advantages and disadvantages of long-acting antipsychotics…

Read More

Pharmacokinetics of Risperidone: Clinical Summary

Author: Flavio Guzman, MD Risperidone is a second-generation antipsychotic metabolized by the enzyme cytochrome P450 2D6 (CYP2D6). It is available as long-acting injection (depot injection) as well as oral formulations. This clinical summary highlights pharmacokinetic features relevant to mental health prescribers. Formulations Oral formulations: Tablets Orally disintegrating tablets Liquid formulation Long-acting injection: risperidone microspheres (Risperdal Consta) General…

Read More

Risperidone Indications: FDA-Approved and Off-Label Uses

By Flavio Guzman, MD. Risperidone is one of the oldest (and least expensive) second-generation antipsychotics. In 1993 the FDA approved it for the treatment of schizophrenia. Like most antipsychotics, risperidone is also effective for the treatment of manic and mixed episodes of bipolar I disorder. It is also one of the few antipsychotics approved for…

Read More